A 2025 review found no clear clinical evidence that low-dose rapamycin extends healthspan in healthy humans, despite promising animal data. The PEARL trial showed some improvements in muscle mass and well-being but larger trials are needed.
PEARL trial findings
- ▪Rapamycin is an FDA-approved immunosuppressant used off-label by some healthy adults seeking longevity benefits
- ▪The PEARL trial found low-dose intermittent rapamycin over 48 weeks was relatively safe and improved lean tissue mass and pain in women
Clinical evidence review
- ▪Animal studies have shown promising results for rapamycin extending lifespan, but human evidence remains insufficient
- ▪A 2025 review found no clear clinical evidence that low-dose rapamycin extends healthspan or delays aging in healthy adults
- ▪Researchers emphasize the urgent need for larger, better-designed human trials before recommending rapamycin for off-label anti-aging use
Debatable claims
- ▪Off-label rapamycin use for longevity is safe enough to recommend to healthy adults now
- ▪The lack of human clinical evidence means rapamycin should not be used off-label for anti-aging until larger trials are completed
Story comments
Loading comments…